Northern Trust’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
Northern Trust's ELVN Position: Q3 2026 in Review
Northern Trust increased its Enliven Therapeutics (ELVN) stake by 24% in Q3 2026, buying an estimated $5.66M and bringing the position to 544,840 shares worth $25M. The position accounts for ﹤0.01% of the portfolio, ranked #1610.
Northern Trust first reported a position in ELVN in Q1 2020 and has held it in 25 quarters since. 216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.
- Northern Trust held 544,840 shares of Enliven Therapeutics worth $25M as of Q3 2026.
- Northern Trust bought 103,902 Enliven Therapeutics shares in Q3 2026, an estimated $5.66M.
- Enliven Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q3 2026, its #1610 holding.
- Northern Trust first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 25 quarters since.
- 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.
Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.